Skip to content
Inciteful Med

Progression and What to Expect with ARSACS

Published: | Updated:

ARSACS is a slowly progressive condition with a normal or near-normal life expectancy. While most individuals will eventually need mobility aids or a wheelchair between their 20s and 40s, proactive physical and occupational therapy can help maintain functional independence for decades.

Key Takeaways

  • • ARSACS is characterized by a very slow progression of spasticity and ataxia over several decades.
  • • Most individuals with classic ARSACS have a normal or near-normal life expectancy.
  • • Transitioning to a wheelchair typically occurs between the late 20s and 40s to preserve energy, prevent falls, and maintain independence.
  • • Doctors use objective clinical tests like the SARA and LEMOCOT scales to track changes in motor coordination over time.
  • • Multidisciplinary care focusing on physical and occupational therapy is essential for adapting to progression and living well.

Understanding the progression of ARSACS is not about predicting a single “end point,” but about gaining the information necessary to plan a life of independence and purpose. While ARSACS is a neurodegenerative (gradually affecting nerve function) condition, its hallmark is its slow progression [1][2]. Changes typically occur over years and decades, giving families and individuals time to adapt, prepare, and utilize the many supportive tools available today.

The Timeline of Mobility

For most individuals with ARSACS, symptoms begin in early childhood, often with a delay in the first steps or a noticeable unsteadiness [3][1]. While everyone’s journey is unique due to different genetic variations and individual health factors, there is a general pattern of change:

  • Early Childhood to Adolescence: During this time, walking is typically independent, though it may be characterized by a wider stance or occasional falls [3][4].
  • Young Adulthood: As spasticity (muscle stiffness) and ataxia (lack of coordination) slowly increase, many individuals begin using assistive devices like canes or walkers to maintain stability and safety [3][5].
  • Late 20s to 40s: Many individuals transition to using a wheelchair for long distances or as their primary mode of mobility during this window [6][7].

(Note: This timeline reflects the classic childhood-onset form of ARSACS. If you have been diagnosed with an adult-onset or atypical variant, your progression will likely be different and you should discuss your specific trajectory with your care team [8].)

It is important to remember that using a wheelchair is not a “failure” of treatment; rather, it is a tool that preserves energy, prevents falls, and can actually increase an individual’s ability to participate in social and professional activities [9][10].

How Doctors Monitor Change

During clinical visits, your medical team will use several objective tests to track how the condition is moving. Understanding these tests can help you feel more engaged in your care:

  1. SARA (Scale for the Assessment and Rating of Ataxia): This is the “gold standard” for measuring coordination. It involves simple tasks like finger-to-nose movements and gait assessment [11][12].
  2. LEMOCOT (Lower Extremity Motor Coordination Test): This test specifically measures how well you can coordinate your legs by having you touch specific targets with your feet [13][12].
  3. 10-Meter Walk Test: A simple timed test to see how quickly and steadily you can walk a short distance [12].
  4. 9-Hole Peg Test: This tracks upper limb dexterity by timing how quickly you can place pegs into holes and remove them. It is a vital measure for understanding hand function [14][15].

These tests are “responsive,” meaning they can detect even small changes over a two-year period, allowing your team to adjust your physical or occupational therapy plan accordingly [16][17].

Long-Term Outlook and Life Expectancy

While ARSACS is a lifelong condition, patients have a normal or near-normal life expectancy [7][18]. The primary goal of long-term management is maintaining functional independence [3]. This is achieved through a multidisciplinary approach:

  • Physical Therapy: Focuses on balance and strength to delay mobility decline [10].
  • Wheelchair Skills Training: Teaching advanced techniques to ensure the user is as independent as possible in their community [19].
  • Occupational Therapy: Helps adapt the home and workplace to maintain hand function and daily living skills [9].

By focusing on these proactive steps, the conversation shifts from “what will be lost” to “how we will continue to live well.” Although the disease progresses, your ability to plan, adapt, and thrive remains within your reach. To help maintain functional independence, you will need to build a strong support system. Learn more in Managing ARSACS: Treatment and Building Your Care Team.

Frequently Asked Questions

What is the life expectancy for someone with ARSACS?
Individuals with ARSACS generally have a normal or near-normal life expectancy. The condition progresses slowly, and the primary focus of medical care is on maintaining functional independence over time.
Will someone with ARSACS eventually need a wheelchair?
Many individuals with classic childhood-onset ARSACS transition to using a wheelchair for long distances by their late 20s to 40s. A wheelchair is often utilized as a helpful tool to preserve energy, prevent falls, and maintain social participation.
How do doctors track the progression of ARSACS?
Neurologists use clinical tests like the SARA and LEMOCOT scales to measure coordination in the arms and legs. They also use walking tests and the 9-Hole Peg Test to objectively track changes in mobility and dexterity over time.
Can physical therapy help with ARSACS progression?
While physical therapy cannot stop the underlying disease, it plays a vital role in managing symptoms. It focuses on maintaining balance and strength, which can help delay mobility decline and preserve independence for as long as possible.
What is the SARA test for ARSACS?
The Scale for the Assessment and Rating of Ataxia (SARA) is a standard clinical tool used to measure coordination. It involves simple tasks like finger-to-nose movements and gait checks to help doctors closely monitor how the disease is changing.

Questions for Your Doctor

  • • What is my (or my child’s) current score on the SARA and LEMOCOT scales, and how will we track this over time?
  • • Based on current gait and balance assessments, what type of mobility aids should we be researching for the next 2-5 years?
  • • Are we seeing any signs of upper limb coordination decline that would benefit from early occupational therapy?
  • • How does the specific SACS mutation identified in our family typically correlate with the speed of progression?
  • • Can you help us coordinate a multidisciplinary team to address physical therapy, occupational therapy, and wheelchair skills training?
  • • Would I benefit from a wheelchair skills clinic?

Questions for You

  • • How has your walking changed in the last year? Are you finding yourself holding onto furniture or people more often?
  • • What daily tasks are becoming more difficult due to hand coordination, and how are you adapting to them?
  • • When you think about your mobility in the future, what are your biggest goals (e.g., continuing to work, traveling, staying active in the community)?
  • • Do you feel you have a support system in place to help you navigate the physical and emotional changes that come with progression?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Spastic ataxias.

    Bereznyakova O, Dupré N

    Handbook of clinical neurology 2018; (155()):191-203 doi:10.1016/B978-0-444-64189-2.00012-3.

    PMID: 29891058
  2. 2

    Absent Foveal Avascular Zone in Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay.

    Douglas VP, Douglas KAA, Miller JB, Gaier ED

    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2021; (41(2)):e166-e168 doi:10.1097/WNO.0000000000001050.

    PMID: 32991389
  3. 3

    Functional mobility in walking adult population with ataxia of Charlevoix-Saguenay.

    Lessard I, St-Gelais R, Hébert LJ, et al.

    Orphanet journal of rare diseases 2021; (16(1)):432 doi:10.1186/s13023-021-02054-2.

    PMID: 34649570
  4. 4

    Case Report: Expanding the Genetic and Phenotypic Spectrum of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay.

    Habibzadeh P, Tabatabaei Z, Inaloo S, et al.

    Frontiers in genetics 2020; (11()):585136 doi:10.3389/fgene.2020.585136.

    PMID: 33414805
  5. 5

    From motor performance to participation: a quantitative descriptive study in adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay.

    Gagnon C, Brais B, Lessard I, et al.

    Orphanet journal of rare diseases 2018; (13(1)):165 doi:10.1186/s13023-018-0898-z.

    PMID: 30231904
  6. 6

    Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) in a Thai Patient: The Classic Clinical Manifestations, Funduscopic Feature, and Brain Imaging Findings with a Novel Mutation in the SACS Gene.

    Srikajon J, Pitakpatapee Y, Limwongse C, et al.

    Tremor and other hyperkinetic movements (New York, N.Y.) 2020; (10()):1 doi:10.5334/tohm.68.

    PMID: 32775015
  7. 7

    Genetics of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) and Role of Sacsin in Neurodegeneration.

    Bagaria J, Bagyinszky E, An SSA

    International journal of molecular sciences 2022; (23(1)) doi:10.3390/ijms23010552.

    PMID: 35008978
  8. 8

    SACS variants are a relevant cause of autosomal recessive hereditary motor and sensory neuropathy.

    Vill K, Müller-Felber W, Gläser D, et al.

    Human genetics 2018; (137(11-12)):911-919 doi:10.1007/s00439-018-1952-6.

    PMID: 30460542
  9. 9

    Wheelchair mobility, motor performance and participation of adult wheelchair users with ARSACS: a cross-sectional study.

    Bourassa J, Routhier F, Gagnon C, et al.

    Disability and rehabilitation. Assistive technology 2023; (18(4)):378-386 doi:10.1080/17483107.2020.1858195.

    PMID: 33307884
  10. 10

    A rehabilitation program to increase balance and mobility in ataxia of Charlevoix-Saguenay: An exploratory study.

    Lessard I, Masterman V, Côté I, et al.

    PloS one 2022; (17(12)):e0279406 doi:10.1371/journal.pone.0279406.

    PMID: 36576926
  11. 11

    Documenting the psychometric properties of the scale for the assessment and rating of ataxia to advance trial readiness of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay.

    Bourcier D, Bélanger M, Côté I, et al.

    Journal of the neurological sciences 2020; (417()):117050 doi:10.1016/j.jns.2020.117050.

    PMID: 32736199
  12. 12

    Assessing mobility and balance in Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay population: Validity and reliability of four outcome measures.

    Lessard I, Brais B, Côté I, et al.

    Journal of the neurological sciences 2018; (390()):4-9 doi:10.1016/j.jns.2018.03.033.

    PMID: 29801904
  13. 13

    Validity and reliability of the LEMOCOT in the adult ARSACS population: A measure of lower limb coordination.

    Lessard I, Lavoie C, Côté I, et al.

    Journal of the neurological sciences 2017; (377()):193-196 doi:10.1016/j.jns.2017.03.046.

    PMID: 28477695
  14. 14

    Reliability and validity of digital health metrics for assessing arm and hand impairments in an ataxic disorder.

    Kanzler CM, Lessard I, Gassert R, et al.

    Annals of clinical and translational neurology 2022; (9(4)):432-443 doi:10.1002/acn3.51493.

    PMID: 35224896
  15. 15

    Computer-based assessment of upper-limb incoordination in autosomal recessive spastic ataxia of Charlevoix-Saguenay patients: A pilot study.

    Bui HT, Audet O, Mathieu J, et al.

    Journal of the neurological sciences 2017; (380()):68-73 doi:10.1016/j.jns.2017.07.013.

    PMID: 28870592
  16. 16

    An exploratory natural history of ataxia of Charlevoix-Saguenay: A 2-year follow-up.

    Gagnon C, Lessard I, Lavoie C, et al.

    Neurology 2018; (91(14)):e1307-e1311 doi:10.1212/WNL.0000000000006290.

    PMID: 30158165
  17. 17

    Natural History of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay: a 4-Year Longitudinal Study.

    Lessard I, Côté I, St-Gelais R, et al.

    Cerebellum (London, England) 2024; (23(2)):489-501 doi:10.1007/s12311-023-01558-w.

    PMID: 37101017
  18. 18

    ARSACS: Clinical Features, Pathophysiology and iPS-Derived Models.

    Salem IH, Blais M, Zuluaga-Sánchez VM, et al.

    Cerebellum (London, England) 2025; (24(1)):24 doi:10.1007/s12311-024-01777-9.

    PMID: 39753868
  19. 19

    Efficacy of Manual Wheelchair Skills Training for Improving Skills and Confidence in People With Hereditary Degenerative Disorders: Protocol for a Sequential Multimethods Study.

    Niyomwungere E, Routhier F, Gagnon C, et al.

    JMIR research protocols 2025; (14()):e66974 doi:10.2196/66974.

    PMID: 40742628

This timeline of ARSACS progression is for educational purposes only. Disease progression varies widely depending on genetic factors, so always consult your neurologist for an accurate assessment of your specific trajectory.

Stay up to date

Get notified when new research about Autosomal recessive spastic ataxia of Charlevoix-Saguenay is published.

No spam. Unsubscribe anytime.